CVGBM is under clinical development by Curevac and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData, Phase I drugs for Glioblastoma Multiforme (GBM) have an 82% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how CVGBM’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

CVGBM overview

CVGBM is under development for the treatment of glioblastoma, melanoma and astrocytoma. It is an mRNA vaccine candidate being developed based on lipid nanoparticle-based mRNA platform. It is administered by intramuscular route.

Curevac overview

Curevac is a clinical-stage biopharmaceutical company that develops RNA-based medicines. The company develops, designs, and produces messenger RNA molecules for therapeutic and prophylactic vaccines in the fields of oncology and infectious diseases. Its product pipeline includes Cv0501, Cv2cov, Flu Sv Mrna and Cvsqiv. Curevac mRNA-based prophylactic vaccine candidates comprise cv7202 and cv8102. it also carries out research and development. The company Cv8102, a lead oncology candidate is designed to modulate the tumor microenvironment. Its products are used in the treatment of prostate cancer and non-small cell lung cancer and infectious diseases such as rabies, rotavirus and influenza. Curevac is headquartered in Tubingen, Baden-Wurttemberg, Germany.

For a complete picture of CVGBM’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.